- Home
- NCRA vs BIAF Comparison
NCRA vs BIAF Comparison
Compare NCRA & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NCRA | BIAF |
|---|---|---|
| Founded | 2002 | 2014 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0M | 5.8M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | NCRA | BIAF |
|---|---|---|
| Price | $0.44 | $1.10 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 82.0K | ★ 143.3K |
| Earning Date | 04-01-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $14,106,275.00 | $6,776,739.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $20.04 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.45 | $0.69 |
| 52 Week High | $2.40 | $46.53 |
Technical Indicators
Market Signals| Indicator | NCRA | BIAF |
|---|---|---|
| Relative Strength Index (RSI) | 30.04 | 47.51 |
| Support Level | $0.45 | $0.69 |
| Resistance Level | $0.58 | $1.17 |
| Average True Range (ATR) | 0.09 | 0.14 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 3.61 | 64.29 |
Price Performance
Historical ComparisonAbout NCRA Nocera Inc.
Nocera Inc is engaged in the manufacturing of aquaculture equipment, construction of aquaculture facilities, managing and operating aquaculture facilities, and consulting for third-party operators of aquaculture facilities. Its primary business operations consist of the design, development, and production of RASs large-scale fish tank systems, for fish farms along with consulting, technology transfer, and aquaculture project management services to new and existing aquaculture management business services.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.